Matches in Nanopublications for { ?s ?p "this is not an innocuous drug it is not recommended for the treatment of asymptomatic hyperuricemia allopurinol reduces serum and urinary uric acid concentrations its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics see clinical pharmacology contraindications warnings precautions allopurinol is indicated in the management of patients with signs and symptoms of primary or secondary gout acute attacks tophi joint destruction uric acid lithiasis and or nephropathy the management of patients with leukemia lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 8 mg day in male patients and 75 mg day in female patients therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks" ?g. }
Showing items 1 to 1 of
1
with 100 items per page.
- association label "this is not an innocuous drug it is not recommended for the treatment of asymptomatic hyperuricemia allopurinol reduces serum and urinary uric acid concentrations its use should be individualized for each patient and requires an understanding of its mode of action and pharmacokinetics see clinical pharmacology contraindications warnings precautions allopurinol is indicated in the management of patients with signs and symptoms of primary or secondary gout acute attacks tophi joint destruction uric acid lithiasis and or nephropathy the management of patients with leukemia lymphoma and malignancies who are receiving cancer therapy which causes elevations of serum and urinary uric acid levels allopurinol treatment should be discontinued when the potential for overproduction of uric acid is no longer present the management of patients with recurrent calcium oxalate calculi whose daily uric acid excretion exceeds 8 mg day in male patients and 75 mg day in female patients therapy in such patients should be carefully assessed initially and reassessed periodically to determine in each case that treatment is beneficial and that the benefits outweigh the risks" assertion.